Please try another search
For the fiscal year ended 31 December 2021, Medipharco Pharmaceutical JSC revenues increased 28% to VND1.294T. Net income increased 66% to VND13.01B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Selling Expense decrease of 30% to VND14.81B (expense), Other Non-Operating Income - Balancing v increase from VND120.3M to VND626.3M (income).
Period Ending: | Dec 31, 2012 | Jun 30, 2012 | Mar 31, 2012 |
---|---|---|---|
Total Revenue | 546567.7 | 160359.72 | 103762.13 |
Gross Profit | 93173.97 | 20391.93 | 20424.23 |
Operating Income | 4781.26 | 465 | 1407.65 |
Net Income | 3166.09 | 372 | 1291.86 |
Period Ending: | Dec 31, 2012 | Jun 30, 2012 | Mar 31, 2012 |
---|---|---|---|
Total Assets | 457821.79 | 372282.28 | |
Total Liabilities | 420206.65 | 336329.68 | |
Total Equity | 37615.14 | 35952.61 |
Period Ending: | Dec 31, 2012 | Jun 30, 2012 | Mar 31, 2012 |
---|---|---|---|
Period Length: | 12 Months | 6 Months | 3 Months |
Cash From Operating Activities | -31122.41 | 195881.02 | 84152.42 |
Cash From Investing Activities | -8239.66 | 0 | 0 |
Cash From Financing Activities | 64686.66 | -191432.48 | -84773.15 |
Net Change in Cash | 25386.79 | 4448.53 | -620.73 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review